VA Natalizumab (Tysabri®) Clinical Monitoring Program
Annual Registry Update

Directions: Please complete registry update annually or as indicated for clinic follow-up (i.e., transfer to another VA, change in status, change in disease type, MRI changes, etc.).

Date of Evaluation: __ __/__ __/__ __ __ __

VAMC Healthcare Provider: _____
VAMC Provider Phone #: _____ Email: _____
Name of VA Facility: _____
VAMC Location (City): _____ State: _____ Facility/Station #: _____

☐ Check here if transferring natalizumab (Tysabri®) treatment from another VA.

Name of Patient (first, last name): _____
Date of Birth: __ __/__ __/__ __ __ __
Patient's Four Digit VA Code: __ __ __ __

1. MS Disease Subtype:
   ☐ Relapsing-remitting ☐ Secondary-progressive with relapses ☐ Progressive-relapsing
2. Number of relapses since starting natalizumab (Tysabri®) (total): _____
3. MS Disability at time of annual evaluation:
   a. Expanded Disability Status Scale (Kurtzke J, et al *Neurology* 1983;13:1444) *check box:*
      ☐0 ☐2.0 ☐3.0 ☐4.0 ☐5.0 ☐6.0 ☐7.0 ☐8.0 ☐9.0
      ☐1.0 ☐2.5 ☐3.5 ☐4.5 ☐5.5 ☐6.5 ☐7.5 ☐8.5 ☐9.5
      ☐1.5

      or

   b. Provider Determined Disease Steps (Hohol M, et al *Neurology* 1995;45:251) *check box:*
      ☐0-Normal ☐4-Late Cane
      ☐1-Mild Disability ☐5-Bilateral Support
      ☐2-Moderate Disability ☐6-Wheelchair
      ☐3-Early Cane
4. Annual Brain MRI by CMSC Protocol (www.va.gov/ms) completed ☐ Date: ___ ______ ___ ___ ___ (mo/yr)
5. Number of months on natalizumab (Tysabri®): _____
6. Number of doses of natalizumab (Tysabri®) to date: _____
7. Untoward effects related to natalizumab (Tysabri®):
   ☐ Hypersensitivity reaction ☐ Infection
   ☐ Hepatotoxicity ☐ Anti-natalizumab antibody
   ☐ Other (list): _____
   a. Number of doses of natalizumab (Tysabri®) given before experiencing untoward effects: _____
   b. Did any of these untoward effects cause discontinuation of natalizumab (Tysabri®)? ☐ yes ☐ no

Please FAX this form to: Alicia Sloan, MPH, LICSW, Natalizumab Clinical Monitoring Program Coordinator
MS Center of Excellence-West, **FAX**: **206-277-4827**, VOICE: 206-277-3593
Questions? Email Alicia.Sloan@va.gov
Visit the MSCoE website at www.va.gov/ms; Note: This monitoring project is not a research protocol.